---
title: Koninklijke Philips N.V. (PHG)
layout: default
nav_order: 532
---

# Koninklijke Philips N.V.
{: .fs-9 }

{: .label .label-purple }

Moat: 2/5

{: .label .label-blue }

Management: 2/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: €27.42 B

Philips' moat rating of 2 out of 5 stems primarily from its brand recognition in certain market segments (e.g., healthcare, personal health) and some customer switching costs, particularly in its healthcare segment where hospitals have integrated Philips' systems and equipment.  This creates some stickiness, though it's far from insurmountable. {: .highlight }
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=PHG+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/PHG/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


However, these advantages are not as pronounced in their consumer product segments where competition is fierce and switching costs are minimal. Furthermore, the increasing commoditization of some of its products erodes pricing power and weakens its competitive advantages. The recent recall of Philips' respironics devices also raises questions about its long-term moat trajectory and impacts brand perception negatively. In the Q2 2020 earnings call, management stated that the Respironics field action had a negative impact on its personal health revenues, and in Q1 2023 management mentioned that the Respironics field action is largely behind them.

**Management:**

{: .important }
The management rating of 2 out of 5 is driven by a few factors. While Philips has taken steps to improve its corporate governance, it has faced some significant challenges in recent years. The Respironics recall is a major blemish on management's track record, highlighting deficiencies in quality control and risk management. In the Q2 2023 earnings call, the CEO acknowledged that quality and regulatory issues will continue to be top priorities.

Furthermore, management's capital allocation decisions have been questionable, with several acquisitions failing to deliver expected returns. Additionally, executive compensation doesn't appear to be strongly tied to intrinsic value creation. In Q1 2021, Philips' CEO mentioned that they are creating a new, simplified operating model, and they believe the plan provides for a clear path to accelerated, high-quality growth.

**Catalyst:**

{: .new }
The catalyst rating of 2 out of 5 reflects a moderate level of potential positive catalysts. The successful resolution of the Respironics recall could improve brand image and unlock value. Management's focus on streamlining operations and exiting non-core businesses could also enhance profitability and focus.

The ongoing restructuring could result in more profitable business segments (Q1 2021 earnings call), including a reduction in excess cash. Additionally, management believes the plan provides for a clear path to accelerated, high-quality growth (Q1 2021 earnings call). However, there is no guarantee that these initiatives will succeed, and the competitive landscape remains challenging.

**Business:**

{: .note }
Philips operates in three main segments: Diagnosis & Treatment, Connected Care, and Personal Health.

* **Diagnosis & Treatment:** This segment includes imaging systems, image-guided therapy, diagnostic informatics, and ultrasound. It is the largest revenue contributor and has the highest margins.
* **Connected Care:** This segment includes patient monitoring, therapeutic care, sleep and respiratory care, and enterprise informatics.
* **Personal Health:** This segment includes oral healthcare, mother and childcare, personal care, male grooming, and domestic appliances. It has lower margins and faces more intense competition.

The healthcare industry is growing, driven by demographic trends and technological advancements. However, competition is fierce, and pricing pressure is increasing. Philips has a strong brand and a global presence but has struggled to deliver consistent growth and profitability.

**Financials:**

Philips' financial performance has been mixed in recent years. Revenue growth has been sluggish, and margins have declined due to restructuring costs (2020 annual report). As indicated in the Q4 2023 earnings call, Philips' net income was severely affected by goodwill impairment in 2020, primarily driven by its diagnosis and treatment operations. Philips' profitability has been historically below that of competitors (Morgan Stanley report, exhibit 5). The company has high debt levels which increase financial risk.

**Valuation:**

{: .warning }
For valuation, a two-stage Discounted Cash Flow (DCF) model is employed. The first stage projects five years of free cash flows based on management's expectations. The second stage uses a growing perpetuity to value the company's terminal value.

**Key Assumptions:**

* **Revenue Growth:** 2.5% for the first five years (in line with historical growth rates) and 2% thereafter (slightly below expected long-term global GDP growth).

* **Operating Margin:** Gradual improvement to 11% over 10 years (in line with current margins) but 10% thereafter (below recent profitability).

* **Capital Expenditures:**  Stable at 6% of revenue.

* **Cost of Capital (WACC):**  8% (reflecting risk premium and financial risk).

**Calculations:**

* **Free Cash Flow (FCF):**  Based on projected revenues, margins, and capital expenditures.

* **Terminal Value:** Calculated using the perpetuity growth method and the terminal year FCF and the long-run growth rate and WACC.
Terminal Value = (FCF in Terminal Year * (1 + long-run growth rate)) / (WACC - long-run growth rate)


* **Present Value of FCF:** Discounted using the WACC.

* **Present Value of Terminal Value:**  Discounted using the WACC.

* **Enterprise Value (EV):** Sum of present value of FCF and present value of terminal value.

* **Equity Value:** EV minus debt plus cash.

* **Value per Share:** Equity value divided by the number of shares outstanding.

**Result:**

{: .highlight }
Based on these pessimistic assumptions, the estimated fair value for Philips is **€27.42 billion**, or **€30.40 per share**, slightly above the market price at the time of this report, indicating a small amount of overvaluation.

**Recent Concerns and Controversies:**

Philips has faced significant challenges related to the recall of its respironics devices. This has resulted in litigation, financial losses, and reputational damage. The company is also dealing with increased pricing pressure and supply chain disruptions. Management has committed to addressing these issues and improving quality control and transparency.  In the Q1 2023 earnings call, the CEO addressed the recall, and in Q2 2023, the company acknowledged that quality and regulatory issues will continue to be top priorities.

**Potential Upcoming Catalysts:**

* **Successful completion of the respironics recall:** This could lead to a re-rating of the stock and unlock value.
* **Improved operational performance:** Streamlining operations and exiting non-core businesses could enhance profitability.
* **Successful acquisitions:** If Philips can identify and execute accretive acquisitions, it could drive growth and create value.
* **New product launches:** Innovative new products could help Philips differentiate itself and gain market share.

**Closing Thoughts:**

Philips is a complex business operating in a challenging environment. While it has some competitive advantages, its moat is not as wide as some other companies in the industry. The recent recall has raised significant concerns about its management and long-term prospects.  A margin of safety is therefore critical when investing in Philips, given its inherent uncertainty. Given the company's recent financial struggles, current market sentiment may be unduly optimistic. Consequently, a very patient investor considering a purchase today should demand a compelling discount to the company’s present intrinsic worth. 

**Disclaimer:** This analysis is for educational purposes only and is not investment advice.  Conduct your own thorough research before making any investment decisions.